Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 0319 • ACR Convergence 2021
Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States
Briana Ndife¹, Irina Pivneva², Carmine Rossi² and James Signorovitch³, ¹Novartis, East Hanover, NJ, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Boston, MA
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disease associated with diverse phenotypes, which may include systemic disease activity. In real-world practice, the clinical presentation…
Abstract Number: 1908 • ACR Convergence 2021
Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Ilir i. Cinoku¹, Kleio-Maria Verrou¹, Evangelia Piperi¹, Michael Voulgarelis², Haralampos Moutsopoulos³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Athens Academy of Athens, Chair Medical Sciences/Immunology, Athens, Greece
Background/Purpose: Primary Sjögren’s syndrome (SS), an autoimmune exocrinopathy, is expressed either as a local disease or as a systemic illness with an enhanced risk for…
Abstract Number: 0304 • ACR Convergence 2021
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Rudrarpan Chatterjee¹, Anu Balakrishnan², Rajat Kharbanda¹, Upendra Rathore¹, Latika Gupta¹, Durga P Misra¹, Vikas Agarwal², Amita Aggarwal¹ and Able Lawrence², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Renal disease in primary Sjogren's syndrome (pSS) can occur in form of tubulointerstitial nephritis (TIN) or glomerulonephritis (GN). Data from India on pSS is…
Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Elena Pontarini³, Michele Bombardieri³, Simon J Bowman⁴ and Hendrika Bootsma², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ⁴Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…
Abstract Number: 1935 • ACR Convergence 2021
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Teressa Shaw¹, Wei Zhang², Sara McCoy³, Xueer Qiu¹, Adam Pagenkopf¹, Robert Hal Scofield⁴, Jacques Galipeau³ and Yun Liang¹, ¹University of Wisconsin-Madison, Madison, WI, ²University of California San Diego, La Jolla, CA, ³University of Wisconsin, Madison, WI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…
Abstract Number: 0305 • ACR Convergence 2021
Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Atsuma Nishiwaki¹, Isamu Yokoe¹, Haraoka Masaki³, Eichi Takaya³, Yousuke Nagasawa¹, Noboru Kitamura¹, Masami Takei¹ and Hideki Nakamura¹, ¹Nihon University School of Medicine, Itabashi, Japan, ²St. Marianna University School of Medicine, kowasaki, Japan, ³St. Marianna University School of Medicine, Kawaski, Japan
Background/Purpose: A recent meta-analysis of cardiovascular diseases demonstrated that the odds of heart failure (HF) was more than 2.54-fold higher in primary Sjögren syndrome (pSS)…
Abstract Number: 0321 • ACR Convergence 2021
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
André van Maurik¹, David Gardner², Saba Nayar², Charlotte Smith², Kenneth Clark¹, Prafull Mistry¹, Rajesh Punwaney³, David Roth³, Robert Henderson¹, Xavier Mariette⁴ and Francesca Barone², ¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ²University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
Abstract Number: 105 • 2019 ACR/ARP Annual Meeting
The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3
Xuan Wang¹, Zhenzhen Wu ¹, Jincheng Pu ¹, Run Feng ¹ and Jianping Tang ¹, ¹1. Department of Rheumatology and Immunology, Tongji Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and lacrimal glands cells form a large part…
Abstract Number: 2878 • 2013 ACR/ARHP Annual Meeting
The Importance Of Germinal Center-Like Structures In Primary Sjögren’s Syndrome Salivary Glands Beyond Lymphoma Risk
Elke Theander¹, Thomas Mandl², Rolf Liedholm³, Roland Jonsson⁴, Malin V. Jonsson⁵ and Gunnar Warfvinge⁶, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, ³Department of oral and maxillofacial surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁶Department of oral pathology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
Background/Purpose: The association between germinal center (GC)-like structures and lymphoma in primary Sjögren's syndrome (pSS) has been demonstrated recently (1). Here we present a comprehensive…
Abstract Number: 2186 • 2012 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Malin V. Jonsson¹, Daniel Hammenfors², Johan G. Brun² and Roland Jonsson³, ¹Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Minor salivary gland biopsy is part of the diagnostic process for primary Sjögren’s syndrome (pSS), but is not suitable for repeated follow-up. Ultrasound (US)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].